The sharp reduction in AQR's disclosed stake from 7.4% to 1.31% suggests significant selling or a change in reporting methodology. Monitor for any further 13G amendments or a potential conversion to a 13D filing if AQR's intent shifts.
SRPT drugs
SRPT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $16.07entry
- T+1 · 19h ago −5.85%α −3.94% · $15.13
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
AQR Capital Management LLC filed an amended Schedule 13G disclosing a 1.31% passive stake in Sarepta Therapeutics as of September 30, 2026, down from its prior 7.4% stake reported three days earlier. The filing confirms passive intent and no control-related purpose.
Key Financial Metrics
Key Facts
- AQR Capital Management LLC disclosed beneficial ownership of 1,386,343 shares of Sarepta common stock, representing 1.31% of shares outstanding as of September 30, 2026.
- The stake includes Convertible Notes representing 990,669 shares of common stock.
- This filing is an amendment to the prior Schedule 13G filed November 10, 2026, which disclosed a 7.4% stake.
- AQR certifies passive investment intent with no purpose of changing or influencing control of the issuer.
Financial Impact
AQR reduced its reported stake from 7.4% to 1.31%, a decrease of approximately 6.1 percentage points.
Risk Factors
- AQR's reduced stake could signal reduced institutional confidence, though the passive filing intent remains unchanged.
- The stake includes convertible notes, which may complicate the true economic exposure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001167557-26-000255 |
| Document: 0001167557-26-000255-index.html | 0001167557-26-000255 |
| Document: 0001167557-26-000255.txt | 0001167557-26-000255 |
Track record
9 reports on SRPT
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Viewing Entry $16.07 Now $15.13 −5.85% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.42 Now $15.13 −7.86% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $17.82 Now $15.13 −15.10% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $18.54 Now $15.13 −18.39% settles Dec 2
- Jul 27, 202616w ago 8-K Neutral 3/10 Entry $15.89 to $18.13 Now $15.13 −4.78% ▲ +14.10% +10.80% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $15.00 to $20.52 Now $15.13 +0.87% ▲ +36.80% +34.91% vs SPY
- Jun 4, 202623w ago 8-K Neutral 3/10 Entry $15.75 to $19.18 Now $15.13 −3.94% ▲ +21.78% +19.92% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $20.89 to $16.67 Now $15.13 −27.56% ▼ −20.18% −25.14% vs SPY
- Feb 25, 202637w ago 8-K Mixed 7/10 Entry $17.45 to $21.68 Now $15.13 −13.30% ▲ +24.24% +30.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers